학술논문
Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers-Do We Have Enough Evidence?
Document Type
Academic Journal
Author
Dubský M; Institute for Clinical and Experimental Medicine, Prague, Czech Republic. mids@ikem.cz.; First Faculty of Medicine, Charles Universtiy, Prague, Czech Republic. mids@ikem.cz.; Husáková J; Institute for Clinical and Experimental Medicine, Prague, Czech Republic.; First Faculty of Medicine, Charles Universtiy, Prague, Czech Republic.; Sojáková D; Institute for Clinical and Experimental Medicine, Prague, Czech Republic.; First Faculty of Medicine, Charles Universtiy, Prague, Czech Republic.; Fejfarová V; Institute for Clinical and Experimental Medicine, Prague, Czech Republic.; Jude EB; Diabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton Under Lyne, UK. Edward.jude@tgh.nhs.uk.; University of Manchester, Lancashire, UK. Edward.jude@tgh.nhs.uk.
Source
Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 101264260 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2000 (Electronic) Linking ISSN: 11771062 NLM ISO Abbreviation: Mol Diagn Ther Subsets: MEDLINE
Subject
Language
English
Abstract
This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in 'no-option' CLTI in the last two decades and more than 1700 patients have received ACT worldwide. Here we analyze the level of published evidence of ACT as well as our experience with this treatment method. Many studies have shown that ACT is safe and an effective method for patients with the most severe lower limb ischemia. However, some trials did not show any benefit of ACT, and there is some heterogeneity in the types of injected cells, route of administration and assessed endpoints. Nevertheless, we believe that ACT plays an important role in a comprehensive treatment of patients with diabetic foot and severe ischemia.
(© 2023. The Author(s).)
(© 2023. The Author(s).)